Alluvi, previously BI 4744, presents a significant development in obesity care. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates impressive efficacy in clinical https://thebookpage.com/story7632206/alluvi-a-detailed-examination-into-the-medication-s-prospects